Minerva Neurosciences
NERV
76 hedge funds and large institutions have $70M invested in Minerva Neurosciences in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
10% more call options, than puts
Call options by funds: $387K | Put options by funds: $352K
0% more funds holding
Funds holding: 76 → 76 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0.41% less ownership
Funds ownership: 9.03% → 8.61% (-0.41%)
27% less capital invested
Capital invested by funds: $95.4M → $70M (-$25.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.22M |
| 3 |
Millennium Management
New York
|
+$1.03M |
| 4 |
Two Sigma Advisers
New York
|
+$738K |
| 5 |
Two Sigma Investments
New York
|
+$729K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.44M |
| 2 |
AG
Artal Group
Luxembourg
|
-$2.42M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
-$1.54M |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
-$1.43M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$666K |
NERV Hedge Fund Activity: Q4 2020 in Review
76 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q4 2020, worth a combined $70M — down 27% from $95.4M a quarter earlier.
Fund positioning in NERV was balanced in Q4 2020: 11 funds opened new positions, 11 closed out, 30 added to existing stakes and 20 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.5M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.44M sold.
- 76 institutional investors held Minerva Neurosciences (NERV) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $70M of Minerva Neurosciences stock for Q4 2020, down 27% quarter-over-quarter.
- 11 funds opened new Minerva Neurosciences positions in Q4 2020 and 11 closed out, a net change of 0 holders.
- The largest Minerva Neurosciences buyer in Q4 2020 was Morgan Stanley, an estimated $1.5M added.
- The largest Minerva Neurosciences seller in Q4 2020 was Opaleye Management, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2020.